Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic alpha-type-1 dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This investigational dendritic cell-based vaccine, developed by Roswell Park Cancer Institute, is designed for the treatment of recurrent prostate cancer. The therapy utilizes autologous dendritic cells that are matured into an alpha-type-1-polarized phenotype (αDC1) using a specific cytokine cocktail (including IL-1β, TNF-α, IFN-α, IFN-γ, and poly-I:C). These matured cells are then loaded with apoptotic bodies from the allogeneic LNCaP prostate cancer cell line, which serves as a source for multiple prostate-specific antigens, including prostatic acid phosphatase (PAP) and prostate-specific membrane antigen (PSMA). Administered intradermally, the vaccine aims to stimulate a robust Th1-polarized cytotoxic T-lymphocyte response against the patient's tumor cells. It has been evaluated in clinical trials in combination with androgen ablation therapy.
- Other names
- alpha-type-1-polarized dendritic cell vaccinealpha-type1-polarized dendritic cell vaccinealpha-type 1-polarized dendritic cell vaccineαDC1 vaccine
02
Targets
PSMA-pMHC (Prostate-specific membrane antigen-derived peptide-MHC complex)
Beyond the preview
Go deeper on allogeneic alpha-type-1 dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic alpha-type-1 dendritic cell vaccine.